Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)

Neil O'Gorman, David Wright, Daniel L Rolnik, Kypros H Nicolaides, Liona C Poon, Neil O'Gorman, David Wright, Daniel L Rolnik, Kypros H Nicolaides, Liona C Poon

Abstract

Introduction: Pre-eclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality. Prophylactic use of low-dose aspirin in women at risk for PE may substantially reduce the prevalence of the disease. Effective screening for PE requiring delivery before 37 weeks (preterm PE) can be provided by a combination of maternal factors, uterine artery Doppler, mean arterial pressure, maternal serum pregnancy-associated plasma protein A and placental growth factor at 11-13 weeks' gestation, with a detection rate of 75% at a false-positive rate of 10%. We present a protocol (V.6, date 25 January 2016) for the ASpirin for evidence-based PREeclampsia prevention (ASPRE) trial, which is a double-blinded, placebo-controlled, randomised controlled trial (RCT) that uses an effective PE screening programme to determine whether low-dose aspirin given to women from 11 to 13 weeks' gestation will reduce the incidence of preterm PE.

Methods and analysis: All eligible women attending for their first trimester scan will be invited to participate in the screening study for preterm PE. Those found to be at high risk of developing preterm PE will be invited to participate in the RCT. Further scans will be conducted for assessment of fetal growth and biomarkers. Pregnancy and neonatal outcomes will be collected and analysed. The first enrolment for the pilot study was in April 2014. As of April 2016, 26 670 women have been screened and 1760 recruited to the RCT. The study is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry.

Trial registration number: ISRCTN13633058.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Flow chart of participants in the screening study and the randomised controlled trial. *Clinical visits at 19–24 and 30–37 weeks will only be performed on screen-negative participants at sites where a scan is performed by the fetal medicine unit as part of the routine clinical care pathway at either of these times. FGR, fetal growth restriction; PE, pre-eclampsia.

References

    1. Witlin GA, Saade GR, Mattar FM et al. . Predictors of neonatal outcome in women with severe pre-eclampsia or eclampsia between 24 and 33 weeks’ gestation. Am J Obstet Gynecol 2000;182:607–11. 10.1067/mob.2000.104224
    1. Irgens HU, Reisaeter L, Irgens LM et al. . Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213–17. 10.1136/bmj.323.7323.1213
    1. von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. Hypertens Pregnancy 2003;22:143–8. 10.1081/PRG-120021060
    1. Yu CK, Khouri O, Onwudiwe N et al. . Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31:310–13. 10.1002/uog.5252
    1. Akolekar R, Syngelaki A, Sarquis R et al. . Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:66–74. 10.1002/pd.2660
    1. Akolekar R, Syngelaki A, Poon L et al. . Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8–15. 10.1159/000341264
    1. Crandon AJ, Isherwood DM. Effect of aspirin on incidence of pre-eclampsia. Lancet 1979;1:1356 10.1016/S0140-6736(79)91996-2
    1. Askie LM, Duley L, Henderson-Smart DJ et al. . Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8. 10.1016/S0140-6736(07)60712-0
    1. Bujold E, Roberge S, Lacasse Y et al. . Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–14. 10.1097/AOG.0b013e3181e9322a
    1. Roberge S, Villa P, Nicolaides K et al. . Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6. 10.1159/000336662
    1. Caron N, Rivard GE, Michon N et al. . Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009;31:1022–7. 10.1016/S1701-2163(16)34346-8
    1. Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol Reprod Biol 2011;157:38–42. 10.1016/j.ejogrb.2011.02.026
    1. Slone D, Siskind V, Heinonen OP et al. . Aspirin and congenital malformations. Lancet 1976;1:1373–5. 10.1016/S0140-6736(76)93025-7
    1. Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology 1988;37:249–55. 10.1002/tera.1420370310
    1. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639–42. 10.1056/NEJM198912143212404
    1. Nørgård B, Puhó E, Czeizel AE et al. . Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005;192:922–3. 10.1016/j.ajog.2004.10.598
    1. Sibai BM, Caritis SN, Thom E et al. . Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993;329:1213–18. 10.1056/NEJM199310213291701
    1. Caritis S, Sibai B, Hauth J et al. . Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;338:701–5. 10.1056/NEJM199803123381101
    1. Rotchell YE, Cruickshank JK, Gay MP et al. . Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998;105:286–92. 10.1111/j.1471-0528.1998.tb10088.x
    1. Sibai BM, Caritis SN, Thom E et al. . Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Am J Obstet Gynecol 1995;172:1553–7. 10.1016/0002-9378(95)90495-6
    1. Di Sessa TG, Moretti ML, Khoury A et al. . Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892–900. 10.1016/S0002-9378(94)70056-7
    1. Schiessl B, Schneider KT, Zimmermann A et al. . Prenatal constriction of the fetal ductus arteriosus—related to maternal pain medication? Z Geburtshilfe Neonatol 2005;209:65–8. 10.1055/s-2005-864116
    1. Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol 2011;14:469–74. 10.2350/07-11-0368.1
    1. Duley L, Henderson-Smart DJ, Meher S et al. . Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;(2):CD004659 . 10.1002/14651858.CD004659.pub2
    1. Poon LCY, Volpe N, Muto B et al. . Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012;32:156–65. 10.1159/000338655
    1. Poon LC, Zymeri NA, Zamprakou A et al. . Protocol for measurement of mean arterial pressure at 11–13 weeks’ gestation. Fetal Diagn Ther 2012;31:42–8. 10.1159/000335366
    1. Plasencia W, Maiz N, Poon L et al. . Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:138–46. 10.1002/uog.5402
    1. Robinson HP, Fleming JE. A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975;182:702–10. 10.1111/j.1471-0528.1975.tb00710.x
    1. Brown MA, Lindheimer MD, de Swiet M et al. . The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV. 10.1081/PRG-100104165
    1. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. J Eur Communities 2001;L 121:34.
    1. National Collaborating Centre for Women's and Children's Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press, 2010.
    1. Wright D, Syngelaki A, Akolekar R et al. . Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213:62.e1–10. 10.1016/j.ajog.2015.02.018
    1. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–96. 10.1159/000324320

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir